Literature DB >> 17921857

Transformation of childhood MDS-refractory anemia to acute lymphoblastic leukemia.

Ruchika Goel1, Rajive Kumar, Sameer Bakhshi.   

Abstract

Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cell. Patients have a deteriorating course with about 30% evolving into acute leukemias usually of the myeloid phenotype. Evolution into acute lymphoblastic leukemia is a rare and intriguing phenomenon seen in far less than 1% of adult cases, and extremely rare in pediatric population. We report a case of childhood MDS-refractory anemia transforming into acute lymphoblastic leukemia after an interval of 21 months since presentation and being on cyclosporine therapy for 9.5 months. The case raises further questions about the biology of MDS and the potential role of cyclosporine in leukemic transformation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921857     DOI: 10.1097/MPH.0b013e31814d6959

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

1.  Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia in a child.

Authors:  Vineeta Gupta; Baldev Bhatia
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-13       Impact factor: 0.900

2.  A rare case of transformation of childhood myelodysplastic syndrome to acute lymphoblastic leukemia.

Authors:  Young Rae Koh; Eun Hae Cho; Seong Shik Park; Mi Young Park; Sun Min Lee; In Suk Kim; Eun Yup Lee
Journal:  Ann Lab Med       Date:  2013-02-21       Impact factor: 3.464

3.  Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: a case report with review of the literature.

Authors:  Ayed A Algarni; Mojtaba Akhtari; Kai Fu
Journal:  Case Rep Hematol       Date:  2012-03-29

4.  Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review.

Authors:  Zhi-Ping Guo; Yan-Hong Tan; Jian-Lan Li; Zhi-Fang Xu; Xiu-Hua Chen; Lian-Rong Xu
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.